Novel approaches targeted toward oxidative stress for the treatment of chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 2, 2008, Pages 143-148

  Swaminathan, Sundararaman ^a   Shah, Sudhir V ^a,b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Catalytic iron; Chronic kidney disease; Diabetic nephropathy; Oxidative stress

Indexed keywords

ANTIOXIDANT; DEFERIPRONE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; IRON; OXIDIZING AGENT; OXYGEN; PIRFENIDONE; PROTEIN KINASE C; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; SULODEXIDE; SUPEROXIDE; TRANSFORMING GROWTH FACTOR;

BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; GLYCOSYLATION; HUMAN; LIPID PEROXIDATION; OUTCOME ASSESSMENT; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION;

BIOLOGICAL MARKERS; CHRONIC DISEASE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DRUGS, INVESTIGATIONAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INDOLES; IRON; KIDNEY; KIDNEY DISEASES; MALEIMIDES; OXIDATIVE STRESS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRIDOXAMINE; REACTIVE OXYGEN SPECIES; TREATMENT OUTCOME; VITAMIN B COMPLEX;

EID: 39149115038     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f4e539     Document Type: Review

References (49)

1. Shah SV, Baliga R, Fonseca VA, Rajapurkar M. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18:16-28. This is a detailed, comprehensive review of experimental evidence for the role of oxidants and iron in chronic kidney disease.
2. McCord JM, Fridovich I. The biology and pathology of oxygen radicals. Ann Intern Med 1978; 89:122-127.
3. Klebanoff S. Myeloperoxidase: friend and foe. J Leukoc Biol 2005; 77:598-625.
4. Malle E, Buch T, Grone HJ. Myeloperoxidase in kidney disease. Kidney Int 2003; 64:1956-1967.
5. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990; 186:1-85.
6. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int Suppl 2000; 77:S26-S30.
7. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414:813-820.
8. Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 2000; 404:787-790.
9. Nishikawa T, Sasahara T, Kiritoshi S. Evaluation of urinary 8-hydroxydeoxyguanosine as a novel biomarker of macrovascular complications in type 2 diabetes. Diabetes Care 2003; 26:1507-1512.
10. Hinokio Y, Suzuki S, Hirai M, et al. Urinary excretion of 8-oxo-7,8-dihydro-2′-deoxyguanosine as a predictor of the development of diabetic nephropathy. Diabetologia 2002; 45:877-882.
11. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295:1681-1687.
12. Horie K, Miyata T, Maeda K, et al. Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 1997; 100:2995-3004.
13. Qian M, Liu M, Eaton JW. Transition metals bind to glycated proteins forming redox active 'glycochelates': Implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun 1998; 250:385-389.
14. Nitenberg A, Pycha F, Ledoux S, et al. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in noninsulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 1998; 97:736-743.
15. Lee D-H, Liu DY, Jacobs DR, et al. Common presence of nontransferrin-bound iron among patients with type 2 diabetes. Diabetes Care 2006; 29:1090-1095.
16. Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care 2007; 30:1926-1933.
17. Rajapurkar MM, Baliga R, Shah SV. Novel treatment for diabetic nephropathy. J Am Soc Nephrol 2007 (in press).
18. Kitada M, Koya D, Sugimoto T, et al. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003; 52:2603-2614.
19. Anderson PW, McGill JB, Tuttle KR. Protein kinase C β inhibition: the promise for treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 2007; 16:397-402.
20. Inoguchi T, Sonta T, Tsubouchi H, et al. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 2003; 8 (Suppl 3):S227-S232.
21. Tuttle KR, Bakris GL, Toto RD, et al. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28:2686-2690.
22. Aiello LP, Davis MD, Girach A, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006; 113:2221-2230.
23. Tuttle KR, McGill JB, Haney DJ, et al. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007; 2:631-636. Collected data from different trials involving more than 1000 patients with a median follow-up of about 3 years demonstrated that, in contrast to an earlier study that demonstrated a reduction in proteinuria, treatment with ruboxistaurin did not appear to halt progression of diabetic nephropathy.
24. Voziyan PA, Hudson BG. Pyridoxamine: the many virtues of a maillard reaction inhibitor. Ann N Y Acad Sci 2005; 1043:807-816.
25. Lal MA, Brismar H, Eklof A-C, Aperia A. Role of oxidative stress in advanced glycation end product-induced mesangial cell activation. Kidney Int 2002; 61:2006-2014.
26. Kannan K, Jain SK. Effect of vitamin B6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H2O2-treated U937 monocytes. Free Radic Biol Med 2004; 36:423-428.
27. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002; 61:939-950.
28. Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007; 27:605-614. This study involving over 200 patients appears to demonstrate a reduction in the rate of progression of renal failure without any differences in urinary albumin excretion.
29. Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13:93-99.
30. Oberg BP, McMenamin E, Lucas FL, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65:1009-1016.
31. Kuo H-T, Kuo M-C, Chiu Y-W, et al. Increased glomerular and extracellular malondialdehyde levels in patients and rats with focal segmental glomerulosclerosis. Eur J Clin Invest 2005; 35:245-250.
32. Descamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, et al. Early prediction of IgA nephropathy progression: Proteinuria and AOPP are strong prognostic markers. Kidney Int 2004; 66:1606-1612.
33. Nankivell BJ, Boadle RA, Harris DCH. Iron accumulation in human chronic renal disease. Am J Kidney Dis 1992; 20:580-584.
34. Rajapurkar MM, Baliga R, Shah SV. Treatment of patients with glomerulonephritis with an oral iron chelator. J Am Soc Nephrol 2007 (in press).
35. Lin J-L, Lin-Tan D-T, Hsu K-H, Yu C-C. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med 2003; 348:277-286.
36. Owda AK, Alam MG, Shah SV. Environmental lead exposure and chronic renal disease. N Engl J Med 2003; 348:1810-1812.
37. Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 2000; 204:119-126.
38. Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2:906-913.
39. Wenzel R, Mann J, Jurgens C. The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy [abstract]. J Am Soc Nephrol 2005; 16:58A.
40. Williams ME. New potential agents in treating diabetic kidney disease: the fourth act. Drugs 2006; 66:2287-2298.
41. Sasser JM, Sullivan JC, Hobbs JL, et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007; 18:143-154.
42. Libby P, Plutzky J. Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 2007; 99 (4A):27B-40B.
43. Takebayashi K, Matsumoto S, Aso Y, Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 2006; 91:2214-2217.
44. Sela S, Shurtz-Swirski R, Shapiro G, et al. Oxidative stress during hemodialysis: effect of heparin. Kidney Int Suppl 2001; 78:S159-S163.
45. Gambaro G, Kinalska I, Oksa A, et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002; 13:1615-1625.
46. Lewis EJ, Lewis JB, Hunsicker LG. Interim analysis of a pilot trial of sulodexide in type 2 diabetic nephropathy with microalbuminuria [abstract]. J Am Soc Nephrol 2005; 16 (Abstracts issue):58A.
47. Alfrey AC, Froment DH, Hammond WS. Role of iron in the tubulo-interstitial injury in nephrotoxic serum nephritis. Kidney Int 1989; 36:753-759.
48. Alfrey AC. Toxicity of tubule fluid iron in the nephrotic syndrome. Am J Physiol 1992; 263:F637-F641.
49. Thomas MC, Burns WC, Cooper MD. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 2005; 12:177-186.